Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage 4.

Trial Profile

Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage 4.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2016 Results of biomarker analysis published in the Anticancer Research
    • 14 Mar 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top